Recent Developments in Helicobacter pylori Eradication Therapy –From Patients to Populations

Recent Developments in Helicobacter pylori Eradication Therapy –From Patients to Populations

European Gastroenterology & Hepatology Review Volume4 Issue 2
Published: October 2009
dots

Helicobacter pylori is a spiral-shaped Gram-negative bacillus that colonises the surface epithelium of the human stomach. Its existence was first confirmed in 1983.1 Prior to this, controversy had surrounded reported observations of bacteria in the stomach. Its discoverers observed that the bacterium was almost always associated with an active chronic gastritis, histologically occurring predominantly in the gastric antrum, and this led them to propose that it might be causally related to peptic ulcer disease and gastric cancer. Since this prescient claim, the aetiological role of H. pylori in both of these diseases has been confirmed by epidemiological studies2–6 and, as a result, in 1994 the bacterium was classified as carcinogenic to humans by the World Health Organization (WHO).7 Between 15 and 30% of individuals in the Western world are infected by the organism,8–10 compared with 80% or more in the Far East.11

Non-invasive detection of H. pylori infection is now a relatively simple task with the advent of the carbon-urea breath test and stool antigen test.12–14 Use of these methods to test for presence of the bacterium is widespread, and treatment with eradication therapy has become commonplace over the last 20 years with the development of H. pylori eradication therapy. This has led to a paradigm shift in the management of many common gastroenterological conditions. Despite huge advances in both the detection and treatment of H. pylori and the understanding of its causative role in gastrointestinal (GI) diseases, there remains some controversy in the management of infected individuals. This article will discuss recent advances in these areas of uncertainty.




To read full article please click here

Keywords:
Helicobacter pylori Eradication Therapy, Helicobacter pylori, Functional Dyspepsia,

Copyright® 2010 Business Briefings, Ltd. All rights reserved.
Touch Gastroenterology is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.